Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer

Fukui, Takafumi; Tachihara, Motoko; Nagano, Tatsuya; Kobayashi, Kazuyuki

doi:10.3390/cancers14051184

Cited by 21 publications

(16 citation statements)

References 108 publications

(112 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NGS can clearly observe the breaking site, so it can clearly know whether the fusion gene formed has normal biological function. In addition, NGS can also predict the therapeutic effect and drug resistance mechanism of drugs by detecting circulating tumor DNA (ctDNA) and circulating free DNA (cfDNA) in the blood, which is expected to improve the prognosis [ 58 ].…”

Section: Detection Methods For Alk Rearrangementsmentioning

confidence: 99%

Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer

et al. 2022

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is the leading cause of cancer-related death. Despite advances in chemotherapy and immunotherapy, the prognosis for advanced patients remains poor. The discovery of oncogenic driver mutations, such as anaplastic lymphoma kinase (ALK) mutations, means that a subset of patients has opportunities for targeted therapy. With the improvement of genetic testing coverage, more and more ALK fusion subtypes and ALK partners have been discovered, and more than 90 rare ALK fusion subtypes have been found in NSCLC. However, unlike the common fusion, echinoderm microtubule-associated protein-like 4 (EML4)-ALK, some rare ALK fusions such as striatin (STRN)-ALK and huntingtin interacting protein 1 (HIP1)-ALK, etc., the large-scale clinical data related to its efficacy are still immature. The clinical application of ALK-tyrosine kinase inhibitors (ALK-TKIs) mainly depends on the positivity of the ALK gene, regardless of the molecular characteristics of the fusion partner. Recent clinical studies in the ALK-positive NSCLC population have demonstrated differences in progression-free survival (PFS) among patients based on different ALK fusion subtypes. This article will introduce the biological characteristics of ALK fusion kinase and common detection methods of ALK fusion and focus on summarizing the differential responses of several rare ALK fusions to ALK-TKIs, and propose corresponding treatment strategies, so as to better guide the application of ALK-TKIs in rare ALK fusion population.

show abstract

Section: Detection Methods For Alk Rearrangementsmentioning

confidence: 99%

Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The incidence of ALK -positive NSCLC is about 3–7%, but its treatment effect is quite satisfactory ( 23 ). Crizotinib is the first targeted drug approved for the treatment of ALK -positive NSCLC ( 24 ).…”

Section: Consensus 3: Adjuvant Target Therapy For Nsclc Patients With...mentioning

confidence: 99%

Expert consensus on perioperative treatment for non-small cell lung cancer

Duan¹,

Tan²,

Bi³

et al. 2022

Transl Lung Cancer Res

View full text Add to dashboard Cite

“…This trial will use a dose de-escalation strategy, followed by a dose-expansion study. A note of caution, however, may be observed from trials evaluating the combination of ALK TKI with immunotherapy, in which toxicity was significantly increased, without signs of greater efficacy [ 94 , 95 ]. Whilst results from these ongoing trials will provide additional data, sample sizes are likely to be small.…”

Section: Future Directions To Evaluate Anti-angiogenic Therapy In ...mentioning

confidence: 99%

Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)

Tan

Pavlakis

2022

IJMS

View full text Add to dashboard Cite

The management of advanced lung cancer has been transformed with the identification of targetable oncogenic driver alterations. This includes anaplastic lymphoma kinase (ALK) gene rearrangements. ALK tyrosine kinase inhibitors (TKI) are established first-line treatment options in advanced ALK rearranged non-small cell lung cancer (NSCLC), with several next-generation ALK TKIs (alectinib, brigatinib, ensartinib and lorlatinib) demonstrating survival benefit compared with the first-generation ALK TKI crizotinib. Still, despite high objective response rates and durable progression-free survival, drug resistance inevitably ensues, and treatment options beyond ALK TKI are predominantly limited to cytotoxic chemotherapy. Anti-angiogenic therapy targeting the vascular endothelial growth factor (VEGF) signaling pathway has shown efficacy in combination with platinum-doublet chemotherapy in advanced NSCLC without a driver alteration, and with EGFR TKI in advanced EGFR mutated NSCLC. The role for anti-angiogenic therapy in ALK rearranged NSCLC, however, remains to be elucidated. This review will discuss the pre-clinical rationale, clinical trial evidence to date, and future directions to evaluate anti-angiogenic therapy in ALK rearranged NSCLC.

show abstract

Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer

Cited by 21 publications

References 108 publications

Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer

Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer

Expert consensus on perioperative treatment for non-small cell lung cancer

Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)

Contact Info

Product

Resources

About